Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pebblebrook Hotel Trust PEB.PR.H


Primary Symbol: PEB Alternate Symbol(s):  PEB.PR.E | PEB.PR.F

Pebblebrook Hotel Trust is a real estate investment trust (REIT) and the owner of urban and resort lifestyle hotels in the United States. The Company owns 46 hotels and resorts, totaling approximately 11,924 guest rooms across 13 urban and resort markets. Its hotel properties include 1 Hotel San Francisco, Argonaut Hotel, Chamberlain West Hollywood Hotel, Chaminade Resort & Spa, Embassy Suites San Diego Bay-Downtown, Estancia La Jolla Hotel & Spa, George Hotel, Harbor Court Hotel San Francisco, Hilton San Diego Gaslamp Quarter, Hotel Monaco Washington DC, Hotel Zelos San Francisco, Hotel Palomar Los Angeles Beverly Hills, Hotel Zeppelin San Francisco, and others. The Company is focused on both branded and independent full-service hotels in the upper-upscale segment of the lodging industry. The full-service hotels on which the Company focuses its investment activity generally have one or more restaurants, lounges, meeting facilities, and other amenities, as well as customer service.


NYSE:PEB - Post by User

Bullboard Posts
Post by Nano2000on Oct 16, 2000 12:25pm
498 Views
Post# 2659621

How Genomics Will Help

How Genomics Will Help The value of the impending genomics revolution is that it will grant researchers the ability to dramatically reduce the time and effort it takes to identify and test promising compounds. Hopefully, this will allow companies to bring drugs to market and achieve profits much more rapidly than previously possible in the biotech industry. This streamlining of the drug discovery process will result in lower costs for companies able to take advantage of genomics, and ultimately higher earnings. Genomics will allow researchers to focus their efforts on the genome, and more specifically individual genes. A gene is a sequence of DNA strands in the genome that carries specific information, such as eye color or bone structure. These genes then transmit their information by creating proteins, which in turn enact changes upon the body. The isolation of individual genes will allow researchers the opportunity to study diseases and genetic conditions at their root. This will allow for tailor made substances that are specifically designed to combat diseases and infirmities. Isolating a gene will aid researchers in discovering how a disease functions, and should ultimately point to opportunities for treatment of that disease. The increase in the level of accuracy that researchers should experience will allow researchers to focus on drugs that are more likely to succeed trials. Costly Phase II and III trial failures may be reduced, as researchers are able to send drugs through the approval process with a much higher success rate than was previously possible. Genetic identification will also allow researchers to screen test subjects to learn which ones have the highest potential to be helped by the drug. This will also allow for the creation of drugs that are much more highly focused and specialized towards individuals. The marketplace may soon offer a high number of individually tailored drugs for different genetic types that will prove more effective for their target markets than the all-encompassing drugs which currently populate the market.
Bullboard Posts